BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 9.04.2025

FDA Clears Doxycycline Oral Suspension for Continued Approval

The FDA has determined that doxycycline oral suspension, 25mg/5mL, was not withdrawn from sale due to safety or effectiveness concerns. This decision allows the FDA to continue approving ANDAs for this product as long as they meet regulatory requirements.

Source: Federal Register — Food and Drug AdministrationOpen original release →